ReviewAAPS PharmSciTech2026
Effective Brain Targeting Using the Self-Emulsifying Drug Delivery Systems.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The administration of neurotherapeutics is severely hindered by the blood-brain barrier (BBB), which limits drug transport to the brain. Self-emulsifying drug delivery systems (SEDDS) offer a promising nanocarrier strategy for improving the solubility, transmembrane permeability across the BBB, and targeted delivery of lipophilic drugs to the central nervous system. This review highlights the formulation principles, excipient selection, and mechanistic insights into SEDDS-mediated enhancement of BBB transport. A critical evaluation of the translational potential and pharmacokinetic benefits of both oral and intranasal SEDDS is presented, along with discussions on innovations in ligand-functionalized, hybrid, and mucoadhesive SEDDS. Additionally, the application of AI/ML-driven optimization tools for preformulation design, along with physiologically based pharmacokinetic (PBPK) modelling, is discussed, and a comparative analysis of reported SEDDS compositions with AI-based formulation predictions is presented. Clinical readiness is assessed through an overview of preclinical outcomes, the patent landscape, and emerging innovation trajectories. This review also addresses key challenges, including excipient safety, scale-up hurdles, and regulatory compliance, providing expert insights into future directions for the clinical translation and optimization of SEDDS for neurotherapeutic delivery.
Indexed as
Identifiers
41872598What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.